Inhibikase Therapeutics Announces $93.6 Million Stock Offering

Inhibikase Therapeutics ( (IKT) ) has provided an announcement.

On November 20, 2025, Inhibikase Therapeutics, Inc. announced an underwriting agreement for a public offering of common stock and pre-funded warrants, expected to raise approximately $93.6 million, with potential to increase to $107.7 million if the underwriters exercise their option in full. This financial move is part of the company’s strategy to support its clinical trial advancements, including the progression of IKT-001 to a global pivotal Phase 3 clinical trial in PAH, reflecting its commitment to expanding its therapeutic offerings in the biotechnology sector.

The most recent analyst rating on (IKT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inhibikase Therapeutics stock, see the IKT Stock Forecast page.

Spark’s Take on IKT Stock

According to Spark, TipRanks’ AI Analyst, IKT is a Neutral.

Inhibikase Therapeutics’ stock score is primarily impacted by its poor financial performance, marked by declining revenues and persistent losses. Technical analysis paints a mixed picture, with short-term indicators slightly positive but overshadowed by longer-term negative trends. Valuation metrics indicate caution due to a negative P/E ratio. The recent leadership change provides a potential positive catalyst for future performance, but its impact remains to be seen.

To see Spark’s full report on IKT stock, click here.

More about Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapeutics for neurological diseases. The company is advancing its product pipeline with a particular emphasis on clinical trials for conditions such as pulmonary arterial hypertension (PAH).

Average Trading Volume: 117,019

Technical Sentiment Signal: Sell

Current Market Cap: $117.3M

See more data about IKT stock on TipRanks’ Stock Analysis page.